During 7 years of followup statin drug use during the trial was not associated with the risk of total prostate cancer ( HR 1.03 , 95 % CI 0.82-1 .30 ) , or lower grade ( HR 0.96 , 95 % CI 0.71-1 .29 ) or higher grade ( HR 1.27 , 95 % CI 0.85-1 .90 ) prostate cancer .